Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations
Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?
Pharma & Biotech
Pharma & Biotech
ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance
Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.
Pharma & Biotech
Can Arvinas, Inc. and Pfizer Inc. scale protein degradation in oncology markets
FDA approves VEPPANU, the first PROTAC therapy. Discover how Arvinas, Inc. is reshaping breast cancer treatment strategies today.
Pharma & Biotech
Can Eli Lilly’s Inluriyo outpace rivals in ESR1-mutated breast cancer after EMBER-3?
Eli Lilly and Company has released updated Phase 3 EMBER-3 results for Inluriyo, also known as imlunestrant, its oral estrogen receptor antagonist, in patients with estrogen receptor-positive and human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. These new data, presented at the 2025 San Antonio Breast Cancer Symposium and published in Annals